Spots Global Cancer Trial Database for Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
Official Title: A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety
Study ID: NCT00434447
Conditions
Interventions
Study Description
Brief Summary: This study is designed to monitor the safety and efficacy of long-term treatment with zoledronic acid by assessing the incidence of, renal impairment, osteonecrosis of the jaw(ONJ), overall safety and skeletal related events (SREs) beyond 12 months treatment
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Canberra, Australian Capital Territory, Australia
Novartis Investigative Site, Concord, New South Wales, Australia
Novartis Investigative Site, Liverpool, New South Wales, Australia
Novartis Investigative Site, Wagga Wagga, New South Wales, Australia
Novartis Investigative Site, Redcliffe, Queensland, Australia
Novartis Investigative Site, Townsville, Queensland, Australia
Novartis Investigative Site, Woolloongabba, Queensland, Australia
Novartis Investigative Site, Ballarat, Victoria, Australia
Novartis Investigative Site, Box Hill, Victoria, Australia
Novartis Investigative Site, Frankston, Victoria, Australia
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmeceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
